Paula H. Lee

Phase I study of pazopanib plus TH-302 in advanced solid tumors

H. Hurwitz, R. Riedel, D. Niedzwiecki, 2017, Cancer Chemotherapy and Pharmacology.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2021, Blood.

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2015, Cancer Chemotherapy and Pharmacology.

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2021 .